Fosamax and Osteonecrosis of the Jaw: Understanding the Medical Evidence for Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Occupational Exposure Awareness

The legacy of general health and science communication has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, audiences have been educated about the importance of bone health and the role of pharmacological interventions in managing conditions such as osteoporosis. This heritage established a framework for discussing how medications interact with physiological processes, emphasizing informed decision-making and awareness of potential adverse effects. As the scope of health information evolved, particular attention turned to the relationship between specific drug exposures and unexpected clinical outcomes. In the domain of mass production, where pharmaceuticals are manufactured and distributed at scale, the transition from general health education to occupational exposure concern becomes critical. Workers involved in the production, handling, and packaging of medications may encounter active pharmaceutical ingredients through inhalation, dermal contact, or accidental ingestion. This occupational context shifts the focus from patient-centered risk communication to workplace safety and industrial hygiene. The same scientific literacy that underpins public health messaging now informs the assessment of exposure thresholds and protective measures for employees. Thus, the bridge from general health information to occupational exposure concern is built upon a shared commitment to understanding how chemical agents—whether consumed therapeutically or encountered occupationally—can influence biological systems, without delving into specific disease mechanisms or citing external evidence.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on this foundation of health literacy and occupational awareness, we now turn to a specific medication and its recognized adverse effect: Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and non-healing extraction sockets. Diagnosis is based on clinical examination and imaging, with a focus on identifying exposed bone persisting for more than eight weeks in the absence of radiation therapy to the jaws.

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate suppress bone turnover, which may impair the jawbone's ability to remodel and repair microdamage, particularly after dental procedures. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that the unique structure and high remodeling rate of the jawbone may make it particularly susceptible to the effects of antiresorptive therapy. Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Warnings and Causation Evidence

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and describes known risk factors. However, the warning also states that in placebo-controlled clinical studies of Fosamax, the percentages of patients with jaw-related symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This may create ambiguity regarding the strength of the association. Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link in some individuals. Additionally, a cohort study among female patients treated for osteoporosis in the United Kingdom found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This data provides a quantitative basis for understanding the risk over time.

Timeline, Management, and Summary

The timeline between exposure and documented harm can vary widely. While some patients develop symptoms within days to months of starting Fosamax, the risk appears to increase with cumulative exposure, as evidenced by the higher risk after longer treatment durations (https://pubmed.ncbi.nlm.nih.gov/39400702/). The condition can also occur spontaneously without an identifiable precipitating event, though it is often associated with dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, antimicrobial therapy, and conservative surgical debridement if necessary. In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer use and in the presence of additional risk factors. The prescribing information includes warnings about this risk, but the clinical trial data showing similar symptom rates between Fosamax and placebo groups may complicate risk communication. Affected patients should consider the temporal relationship, duration of therapy, and presence of other risk factors when evaluating causation. The risk, while low in absolute terms, increases significantly with prolonged exposure and warrants careful monitoring and preventive dental care.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication approved for treating and preventing osteoporosis. It works by inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition of exposed necrotic bone in the jaw, often associated with dental procedures. Fosamax use increases ONJ risk, especially with longer duration and additional risk factors like invasive dental work (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, periodontal disease, anemia, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How strong is the evidence linking Fosamax to ONJ?

Evidence includes temporal relationships, symptom relief upon discontinuation, recurrence on rechallenge, and cohort studies showing increased risk with longer use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, clinical trials showed similar jaw symptom rates between Fosamax and placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.